focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.20
Bid: 112.00
Ask: 113.00
Change: -2.60 (-2.26%)
Spread: 1.00 (0.893%)
Open: 114.00
High: 114.20
Low: 112.20
Prev. Close: 114.80
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs

Mon, 21st Dec 2020 15:43

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Friday and Monday and not separately reported by Alliance News:

----------

Ferguson PLC - Wokingham, Berkshire-based plumbing and heating products - Hires Suzanne Wood and Brian May as non-executive directors, starting January 1. Wood has been chief financial officer of Vulcan Materials Co, a US producer of construction aggregates, since 2018. Prior to that she was CFO of equipment rental company Ashtead Group PLC. May was CFO of distribution and services firm Bunzl PLC for 14 years before retiring in late 2019. May is currently a non-executive director of water works United Utilities Group PLC and of medical technology company ConvaTec Group PLC

----------

easyJet PLC - Luton Airport-based budget airline - Independent Non-Executive Director Anastassia Lauterbach resigns from board, effective immediately, and so won't stand for re-election at easyJet's annual general meeting on Wednesday.

----------

Direct Line Insurance Group PLC - Bromley, Kent-based motor insurer - Jane Hanson will step down as independent non-executive director at AGM in May, having served for over nine years. Adrian Joseph is hired as a new non-executive director, starting January 1. Joseph is managing director, Group AI & Data Solutions at BT Group PLC. Previously, he was a senior partner at accountants EY and also spent 10 years at Alphabet Inc's Google.

----------

Burford Capital Ltd - London-based law suit finance - Hires Andrea Muller as non-executive director. Muller was a European partner at law firm Shearman & Sterling. Most recently, she was global head of Institutional Business at Principal Global Investors. Muller will be Burford's first female board member.

----------

Distil PLC - London-based premium alcohol brands - Hires Roland Grain as non-executive director, replacing Mark Quinn, effective January 1. Grain is an owner and investor in the spirits industry, including being the owner of Potstill Spirits Trading GmbH, Austria's largest whisky importer and distributor. Distil additionally promotes Marking & Operations Director Kate O'Connell to the board, also from January 1. O'Connell joined Distil as marketing manager in 2011. The company plans to appoint an independent non-executive director and will start looking in the new year.

----------

Syncona Ltd - London-based life sciences investor - Hires Virginia Holmes as non-executive director, starting January 1. Holmes was chief executive of AXA Investment Managers UK, part of French insurer AXA SA, and prior to that was an executive at lender Barclays PLC for more than a decade.

----------

Amur Minerals Corp - nickel-copper sulphide mineral exploration and development in far east of Russia - CFO Paul McKay to leave company on December 31. Contracts with Heytesbury Corporate LLP to provide company secretarial and accounting services.

----------

Henderson International Income Trust PLC - seeks income from non-UK investments - Hires Joanne Parfrey as non-executive director, starting January 1. Parfrey is a chartered accountant who currently is a non-executive director of Octopus AIM VCT PLC, among other positions.

----------

Block Energy PLC - development and production in Georgia - Hires Dato Sandroshvili as independent non-executive director, effective immediately. Sandroshvili is CFO of New Age (African Global Energy) Ltd. Previously, he was director of Strategy, Commercial & Portfolio at former London listing Ophir Energy PLC.

----------

Kainos Group PLC - London-based IT provider with Digital Services and Workday Practice businesses - Hires Rosaleen Blair as non-executive director, starting January 1. Blair is founder & chair of Alexander Mann Solutions, which provides workforce solutions, and had served as its chief executive for 23 years.

----------

FBD Holdings PLC - Dublin-based property and casualty insurer - Confirms Tomas O'Midheach will join as CEO on January 4, replacing Interim CEO Paul D'Alton. FBD had announced O'Midheach's appointment back in July. He left Dublin-based lender AIB Group PLC after 14 years in November, ending as AIB's chief operating officer.

----------

River & Mercantile UK Micro Cap Investment Co Ltd - Hires Stephen Coe as non-executive director, starting January 1. Coe is a chartered accountant, specialising in offshore investment funds. He currently is a non-executive director of Weiss Korea Opportunity Fund Ltd and of Merian Chrysalis Investment Co Ltd, which changed its name on Monday to Chrysalis Investments Ltd.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 May 2024 14:34

Syncona notes Autolus's first quarter loss widens amid higher costs

(Alliance News) - Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs.

Read more
9 May 2024 13:58

IN BRIEF: Syncona's Freeline gets positive results for Gaucher disease

Syncona Ltd on Thursday - London-based investor in healthcare companies - Says UK portfolio company Freeline Therapeutics Ltd presents positive new data from its phase I and II Galileo-1 study of FLT201, its novel gene therapy candidate, in Gaucher disease. Says FLT201 demonstrates a favourable safety and tolerability profile, with no infusion reactions and no severe adverse events. Syncona notes that Gaucher disease is a "debilitating genetic disorder caused by a deficiency of the GCase enzyme". Syncona Chief Executive Officer Chris Hollowood says: "We are very encouraged by the data generated from FLT201 which demonstrates a favourable safety and tolerability profile and significant enzyme activity. We are confident this treatment has the potential to challenge the standard of care in Gaucher disease, where current treatments are life-long and do not fully alleviate the disease." Freeline Therapeutics is based in Stevenage, Hertfordshire.

Read more
9 May 2024 11:19

Syncona reports positive findings from investee Freeline

(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.

Read more
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.